What’s Bio-Rad Laboratories, Inc. (BIO) Upside After Making 52-Week High?

May 22, 2018 - By Darrin Black

Bio-Rad Laboratories, Inc. (NYSE:BIO) Logo

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.35, from 0.78 in 2017Q3. It is positive, as 23 investors sold Bio-Rad Laboratories, Inc. shares while 89 reduced holdings. 44 funds opened positions while 82 raised stakes. 18.57 million shares or 0.31% more from 18.51 million shares in 2017Q3 were reported.
Fmr Limited Liability Company holds 144,095 shares or 0% of its portfolio. Barclays Plc invested in 7,537 shares or 0% of the stock. Bluemountain Cap Mngmt Ltd Liability Co accumulated 10,791 shares. 1,000 are owned by Pacad Investment. Northwestern Mutual Wealth has invested 0% in Bio-Rad Laboratories, Inc. (NYSE:BIO). The Missouri-based Amer Century Cos has invested 0.14% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Dorsey Wright & Assoc stated it has 8,269 shares. Fort Washington Oh reported 325,985 shares stake. Alliancebernstein L P invested 0.06% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Synovus Fincl invested in 0% or 970 shares. Eagle Asset has 41,110 shares. State Board Of Administration Of Florida Retirement accumulated 0.02% or 30,736 shares. Neuberger Berman Gru Lc has 131,273 shares for 0.04% of their portfolio. Stewart Patten Company Lc reported 2,668 shares. Manufacturers Life The invested in 0.05% or 212,878 shares.

Since December 14, 2017, it had 0 buys, and 1 insider sale for $1.24 million activity.

The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) hit a new 52-week high and has $310.24 target or 6.00 % above today’s $292.68 share price. The 5 months bullish chart indicates low risk for the $8.64 billion company. The 1-year high was reported on May, 22 by Barchart.com. If the $310.24 price target is reached, the company will be worth $518.28M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.14% or $0.4 during the last trading session, reaching $292.68. About 12,228 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 25.02% since May 22, 2017 and is uptrending. It has outperformed by 13.47% the S&P500.

Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on August, 2. They expect $1.25 earnings per share, up 115.52 % or $0.67 from last year’s $0.58 per share. BIO’s profit will be $36.89 million for 58.54 P/E if the $1.25 EPS becomes a reality. After $1.17 actual earnings per share reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts 6.84 % EPS growth.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Ratings Coverage

Among 3 analysts covering Bio-Rad Laboratories (NYSE:BIO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Bio-Rad Laboratories had 5 analyst reports since November 29, 2017 according to SRatingsIntel. Wells Fargo maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) on Wednesday, November 29 with “Buy” rating. The company was maintained on Tuesday, March 20 by Wells Fargo. The rating was maintained by Wells Fargo on Wednesday, February 28 with “Outperform”. The stock has “Neutral” rating by CL King on Friday, February 16. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) earned “Hold” rating by C.L. King on Friday, February 16.

More important recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” on May 15, 2018, also Businesswire.com published article titled: “Bio-Rad Reports First Quarter 2018 Financial Results”, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” on May 17, 2018. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) was released by: Globenewswire.com and their article: “Research Report Identifies Bio-Rad Laboratories, Bright Horizons Family Solutions, Corbus Pharmaceuticals …” with publication date: May 18, 2018.

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company has market cap of $8.64 billion. The firm operates through two divisions, Life Science and Clinical Diagnostics. It has a 76.62 P/E ratio. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.